Penumbra, Inc. (NYSE:PEN) Director Sells $28,615.00 in Stock

Penumbra, Inc. (NYSE:PEN) Director Bridget O’rourke sold 100 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $286.15, for a total transaction of $28,615.00. Following the completion of the transaction, the director now owns 5,423 shares in the company, valued at $1,551,791.45. This represents a 1.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bridget O’rourke also recently made the following trade(s):

• On Tuesday, April 15th, Bridget O’rourke sold 50 shares of Penumbra stock. The shares were sold at an average price of $271.21, for a total transaction of $13,560.50.
• On Monday, March 3rd, Bridget O’rourke sold 50 shares of Penumbra stock. The shares were sold at an average price of $285.48, for a total transaction of $14,274.00.

Penumbra Stock Performance

NYSE:PEN opened at $281.10 on Monday. The firm’s fifty day moving average price is $279.37 and its 200 day moving average price is $263.96. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The firm has a market cap of $10.89 billion, a price-to-earnings ratio of 826.76, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million. During the same period last year, the firm posted $0.41 EPS. Penumbra’s quarterly revenue was up 16.3% on a year-over-year basis. On average, sell-side analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

Institutional Investors Weigh In On Penumbra

A number of hedge funds and other institutional investors have recently bought and sold shares of PEN. Synergy Investment Management LLC acquired a new stake in Penumbra in the first quarter valued at $27,000. First Horizon Advisors Inc. lifted its holdings in Penumbra by 404.8% in the first quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock valued at $28,000 after acquiring an additional 85 shares during the period. UMB Bank n.a. lifted its holdings in Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after acquiring an additional 70 shares during the period. Hurley Capital LLC acquired a new stake in Penumbra in the fourth quarter valued at $56,000. Finally, Huntington National Bank lifted its holdings in Penumbra by 138.7% in the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after acquiring an additional 154 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Robert W. Baird increased their price target on shares of Penumbra from $316.00 to $325.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Morgan Stanley lifted their target price on shares of Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, February 19th. Canaccord Genuity Group lifted their target price on shares of Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Wells Fargo & Company lifted their target price on shares of Penumbra from $305.00 to $315.00 and gave the company an “overweight” rating in a report on Thursday, April 24th. Finally, Stifel Nicolaus set a $318.00 target price on shares of Penumbra and gave the company a “buy” rating in a report on Thursday, April 24th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.